Intrinsic value of Achaogen - AKAO

Previous Close

$1.93

  Intrinsic Value

$1.38

stock screener

  Rating & Target

sell

-28%

Previous close

$1.93

 
Intrinsic value

$1.38

 
Up/down potential

-28%

 
Rating

sell

We calculate the intrinsic value of AKAO stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 0.1

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  60.00
  54.50
  49.55
  45.10
  41.09
  37.48
  34.23
  31.31
  28.68
  26.31
  24.18
  22.26
  20.53
  18.98
  17.58
  16.32
  15.19
  14.17
  13.26
  12.43
  11.69
  11.02
  10.42
  9.87
  9.39
  8.95
  8.55
  8.20
  7.88
  7.59
Revenue, $m
  18
  28
  41
  60
  85
  116
  156
  205
  264
  333
  414
  506
  609
  725
  853
  992
  1,142
  1,304
  1,477
  1,661
  1,855
  2,059
  2,274
  2,498
  2,733
  2,978
  3,232
  3,497
  3,773
  4,059
Variable operating expenses, $m
  39
  60
  90
  131
  185
  254
  341
  447
  575
  727
  902
  1,103
  1,330
  1,582
  1,860
  2,164
  2,493
  2,846
  3,223
  3,624
  4,048
  4,494
  4,962
  5,452
  5,963
  6,497
  7,053
  7,631
  8,232
  8,857
Fixed operating expenses, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  39
  60
  90
  131
  185
  254
  341
  447
  575
  727
  902
  1,103
  1,330
  1,582
  1,860
  2,164
  2,493
  2,846
  3,223
  3,624
  4,048
  4,494
  4,962
  5,452
  5,963
  6,497
  7,053
  7,631
  8,232
  8,857
Operating income, $m
  -21
  -33
  -49
  -71
  -100
  -137
  -184
  -242
  -312
  -394
  -489
  -598
  -720
  -857
  -1,008
  -1,172
  -1,350
  -1,542
  -1,746
  -1,963
  -2,193
  -2,434
  -2,688
  -2,953
  -3,230
  -3,519
  -3,821
  -4,134
  -4,459
  -4,798
EBITDA, $m
  -19
  -29
  -44
  -64
  -90
  -123
  -166
  -217
  -280
  -353
  -439
  -537
  -647
  -770
  -905
  -1,053
  -1,212
  -1,384
  -1,568
  -1,763
  -1,969
  -2,186
  -2,413
  -2,652
  -2,900
  -3,160
  -3,430
  -3,711
  -4,004
  -4,308
Interest expense (income), $m
  2
  3
  3
  8
  14
  23
  34
  49
  68
  90
  118
  150
  188
  230
  279
  333
  392
  457
  527
  602
  683
  768
  858
  954
  1,053
  1,158
  1,267
  1,381
  1,499
  1,623
  1,751
Earnings before tax, $m
  -24
  -36
  -57
  -85
  -123
  -172
  -234
  -310
  -402
  -511
  -639
  -785
  -951
  -1,136
  -1,340
  -1,564
  -1,807
  -2,069
  -2,348
  -2,646
  -2,961
  -3,293
  -3,641
  -4,007
  -4,388
  -4,786
  -5,201
  -5,633
  -6,082
  -6,549
Tax expense, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Net income, $m
  -24
  -36
  -57
  -85
  -123
  -172
  -234
  -310
  -402
  -511
  -639
  -785
  -951
  -1,136
  -1,340
  -1,564
  -1,807
  -2,069
  -2,348
  -2,646
  -2,961
  -3,293
  -3,641
  -4,007
  -4,388
  -4,786
  -5,201
  -5,633
  -6,082
  -6,549

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  76
  118
  177
  256
  361
  497
  667
  876
  1,127
  1,423
  1,767
  2,161
  2,605
  3,099
  3,644
  4,238
  4,882
  5,574
  6,313
  7,098
  7,927
  8,801
  9,718
  10,677
  11,680
  12,725
  13,813
  14,945
  16,123
  17,347
Adjusted assets (=assets-cash), $m
  76
  118
  177
  256
  361
  497
  667
  876
  1,127
  1,423
  1,767
  2,161
  2,605
  3,099
  3,644
  4,238
  4,882
  5,574
  6,313
  7,098
  7,927
  8,801
  9,718
  10,677
  11,680
  12,725
  13,813
  14,945
  16,123
  17,347
Revenue / Adjusted assets
  0.237
  0.237
  0.232
  0.234
  0.235
  0.233
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
  0.234
Average production assets, $m
  15
  23
  34
  49
  69
  95
  128
  168
  216
  273
  340
  415
  500
  595
  700
  814
  938
  1,071
  1,213
  1,364
  1,523
  1,691
  1,867
  2,051
  2,244
  2,445
  2,654
  2,871
  3,097
  3,333
Working capital, $m
  -33
  -52
  -77
  -112
  -158
  -217
  -291
  -383
  -492
  -622
  -772
  -944
  -1,138
  -1,354
  -1,592
  -1,852
  -2,133
  -2,435
  -2,758
  -3,101
  -3,463
  -3,845
  -4,245
  -4,665
  -5,103
  -5,559
  -6,035
  -6,529
  -7,044
  -7,578
Total debt, $m
  28
  66
  118
  190
  285
  407
  560
  747
  974
  1,240
  1,550
  1,904
  2,303
  2,748
  3,239
  3,774
  4,353
  4,976
  5,641
  6,347
  7,094
  7,880
  8,705
  9,569
  10,471
  11,412
  12,391
  13,410
  14,470
  15,571
Total liabilities, $m
  69
  106
  159
  231
  325
  447
  600
  788
  1,014
  1,281
  1,591
  1,945
  2,344
  2,789
  3,279
  3,815
  4,394
  5,017
  5,682
  6,388
  7,135
  7,921
  8,746
  9,609
  10,512
  11,452
  12,432
  13,451
  14,511
  15,612
Total equity, $m
  8
  12
  18
  26
  36
  50
  67
  88
  113
  142
  177
  216
  260
  310
  364
  424
  488
  557
  631
  710
  793
  880
  972
  1,068
  1,168
  1,272
  1,381
  1,495
  1,612
  1,735
Total liabilities and equity, $m
  77
  118
  177
  257
  361
  497
  667
  876
  1,127
  1,423
  1,768
  2,161
  2,604
  3,099
  3,643
  4,239
  4,882
  5,574
  6,313
  7,098
  7,928
  8,801
  9,718
  10,677
  11,680
  12,724
  13,813
  14,946
  16,123
  17,347
Debt-to-equity ratio
  3.680
  5.560
  6.700
  7.410
  7.880
  8.180
  8.390
  8.540
  8.640
  8.710
  8.770
  8.810
  8.840
  8.870
  8.890
  8.900
  8.920
  8.930
  8.940
  8.940
  8.950
  8.950
  8.960
  8.960
  8.970
  8.970
  8.970
  8.970
  8.970
  8.980
Adjusted equity ratio
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100
  0.100

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -24
  -36
  -57
  -85
  -123
  -172
  -234
  -310
  -402
  -511
  -639
  -785
  -951
  -1,136
  -1,340
  -1,564
  -1,807
  -2,069
  -2,348
  -2,646
  -2,961
  -3,293
  -3,641
  -4,007
  -4,388
  -4,786
  -5,201
  -5,633
  -6,082
  -6,549
Depreciation, amort., depletion, $m
  2
  3
  5
  7
  10
  14
  19
  25
  32
  40
  50
  61
  74
  88
  103
  120
  138
  157
  178
  201
  224
  249
  275
  302
  330
  359
  390
  422
  456
  490
Funds from operations, $m
  -22
  -33
  -52
  -78
  -113
  -158
  -215
  -285
  -370
  -471
  -589
  -724
  -877
  -1,048
  -1,237
  -1,444
  -1,669
  -1,911
  -2,170
  -2,445
  -2,737
  -3,044
  -3,367
  -3,705
  -4,058
  -4,427
  -4,811
  -5,211
  -5,627
  -6,059
Change in working capital, $m
  -13
  -18
  -26
  -35
  -46
  -59
  -74
  -91
  -110
  -130
  -150
  -172
  -194
  -216
  -238
  -260
  -281
  -302
  -323
  -343
  -362
  -382
  -400
  -419
  -438
  -457
  -476
  -495
  -514
  -535
Cash from operations, $m
  -9
  -15
  -26
  -43
  -67
  -99
  -141
  -194
  -261
  -342
  -439
  -552
  -683
  -832
  -999
  -1,185
  -1,388
  -1,609
  -1,847
  -2,102
  -2,374
  -2,662
  -2,966
  -3,286
  -3,620
  -3,970
  -4,336
  -4,716
  -5,112
  -5,524
Maintenance CAPEX, $m
  -1
  -2
  -3
  -5
  -7
  -10
  -14
  -19
  -25
  -32
  -40
  -50
  -61
  -74
  -88
  -103
  -120
  -138
  -157
  -178
  -201
  -224
  -249
  -275
  -302
  -330
  -359
  -390
  -422
  -456
New CAPEX, $m
  -6
  -8
  -11
  -15
  -20
  -26
  -33
  -40
  -48
  -57
  -66
  -76
  -85
  -95
  -105
  -114
  -124
  -133
  -142
  -151
  -159
  -168
  -176
  -184
  -193
  -201
  -209
  -218
  -226
  -235
Cash from investing activities, $m
  -7
  -10
  -14
  -20
  -27
  -36
  -47
  -59
  -73
  -89
  -106
  -126
  -146
  -169
  -193
  -217
  -244
  -271
  -299
  -329
  -360
  -392
  -425
  -459
  -495
  -531
  -568
  -608
  -648
  -691
Free cash flow, $m
  -16
  -25
  -41
  -63
  -94
  -135
  -187
  -253
  -334
  -431
  -545
  -678
  -830
  -1,001
  -1,192
  -1,402
  -1,631
  -1,880
  -2,147
  -2,432
  -2,734
  -3,054
  -3,391
  -3,745
  -4,115
  -4,501
  -4,904
  -5,324
  -5,761
  -6,215
Issuance/(repayment) of debt, $m
  6
  37
  53
  72
  95
  122
  153
  188
  226
  267
  310
  354
  399
  445
  490
  535
  580
  623
  665
  706
  747
  786
  825
  864
  902
  941
  980
  1,019
  1,060
  1,101
Issuance/(repurchase) of shares, $m
  47
  40
  63
  93
  133
  185
  251
  331
  427
  541
  673
  825
  995
  1,185
  1,395
  1,624
  1,871
  2,138
  2,422
  2,724
  3,044
  3,380
  3,733
  4,102
  4,488
  4,891
  5,310
  5,746
  6,200
  6,671
Cash from financing (excl. dividends), $m  
  53
  77
  116
  165
  228
  307
  404
  519
  653
  808
  983
  1,179
  1,394
  1,630
  1,885
  2,159
  2,451
  2,761
  3,087
  3,430
  3,791
  4,166
  4,558
  4,966
  5,390
  5,832
  6,290
  6,765
  7,260
  7,772
Total cash flow (excl. dividends), $m
  37
  53
  74
  101
  134
  172
  217
  266
  320
  377
  438
  501
  565
  629
  694
  757
  820
  881
  941
  999
  1,056
  1,112
  1,167
  1,222
  1,276
  1,330
  1,386
  1,442
  1,499
  1,558
Retained Cash Flow (-), $m
  -47
  -40
  -63
  -93
  -133
  -185
  -251
  -331
  -427
  -541
  -673
  -825
  -995
  -1,185
  -1,395
  -1,624
  -1,871
  -2,138
  -2,422
  -2,724
  -3,044
  -3,380
  -3,733
  -4,102
  -4,488
  -4,891
  -5,310
  -5,746
  -6,200
  -6,671
Prev. year cash balance distribution, $m
  138
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  128
  13
  12
  8
  1
  -13
  -34
  -65
  -108
  -164
  -235
  -324
  -430
  -556
  -701
  -866
  -1,052
  -1,257
  -1,482
  -1,725
  -1,988
  -2,268
  -2,566
  -2,881
  -3,213
  -3,561
  -3,925
  -4,305
  -4,701
  -5,113
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  122
  12
  10
  7
  0
  -9
  -23
  -41
  -62
  -86
  -112
  -138
  -164
  -187
  -206
  -220
  -229
  -231
  -228
  -219
  -206
  -188
  -168
  -147
  -125
  -104
  -84
  -67
  -51
  -39
Current shareholders' claim on cash, %
  50.0
  5.9
  0.7
  0.1
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0
  0.0

Achaogen, Inc. is a late-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections. The Company is involved in researching and developing plazomicin, its lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infection (cUTI), blood stream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). Plazomicin is an intravenous aminoglycoside antibiotic. The Company has developed plazomicin by chemically modifying sisomicin, a naturally occurring aminoglycoside, in order to overcome common aminoglycoside resistance mechanisms. The Company has a portfolio of small molecule and antibody programs. The Company's Early Development programs include C-Scape and LpxC.

FINANCIAL RATIOS  of  Achaogen (AKAO)

Valuation Ratios
P/E Ratio -1
Price to Sales 1.6
Price to Book 0.6
Price to Tangible Book
Price to Cash Flow -1.5
Price to Free Cash Flow -1.4
Growth Rates
Sales Growth Rate 61.5%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate NaN%
Financial Strength
Quick Ratio 37
Current Ratio 0
LT Debt to Equity 19.6%
Total Debt to Equity 23.4%
Interest Coverage -35
Management Effectiveness
Return On Assets -59.7%
Ret/ On Assets - 3 Yr. Avg. -47.7%
Return On Total Capital -74.7%
Ret/ On T. Cap. - 3 Yr. Avg. -56.2%
Return On Equity -94.7%
Return On Equity - 3 Yr. Avg. -66.5%
Asset Turnover 0.4
Profitability Ratios
Gross Margin 0%
Gross Margin - 3 Yr. Avg. 0%
EBITDA Margin -164.3%
EBITDA Margin - 3 Yr. Avg. -122.7%
Operating Margin -116.7%
Oper. Margin - 3 Yr. Avg. -106.8%
Pre-Tax Margin -169%
Pre-Tax Margin - 3 Yr. Avg. -124.3%
Net Profit Margin -169%
Net Profit Margin - 3 Yr. Avg. -124.3%
Effective Tax Rate 0%
Eff/ Tax Rate - 3 Yr. Avg. 0%
Payout Ratio 0%

AKAO stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the AKAO stock intrinsic value calculation we used $11.175 million for the last fiscal year's total revenue generated by Achaogen. The default revenue input number comes from 0001 income statement of Achaogen. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our AKAO stock valuation model: a) initial revenue growth rate of 60% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for AKAO is calculated based on our internal credit rating of Achaogen, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Achaogen.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of AKAO stock the variable cost ratio is equal to 218.2%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for AKAO stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 12.1% for Achaogen.

Corporate tax rate of 27% is the nominal tax rate for Achaogen. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the AKAO stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for AKAO are equal to 82.1%.

Life of production assets of 6.8 years is the average useful life of capital assets used in Achaogen operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for AKAO is equal to -186.7%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $121.962 million for Achaogen - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 44.796 million for Achaogen is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Achaogen at the current share price and the inputted number of shares is $0.1 billion.

RELATED COMPANIES Price Int.Val. Rating
TTPH Tetraphase Pha 2.05 0.63  str.sell
EBS Emergent Bioso 66.74 3.72  str.sell
CRMD CorMedix 1.10 0.07  str.sell
OTIC Otonomy 2.41 0.96  str.sell
IONS Ionis Pharmace 51.73 6.10  str.sell

COMPANY NEWS

▶ Achaogen: 3Q Earnings Snapshot   [08:10AM  Associated Press]
▶ 4 months after drug approval, Achaogen eyes fire sale   [Nov-05-18 05:16PM  American City Business Journals]
▶ [$$] Drug Company Achaogen Expresses Doubt About Its Viability   [Aug-07-18 05:45PM  The Wall Street Journal]
▶ Achaogen: 2Q Earnings Snapshot   [05:04PM  Associated Press]
▶ Achaogen, Inc. to Host Earnings Call   [02:30PM  ACCESSWIRE]
▶ A guide to biotechs building boom in South City   [03:47PM  American City Business Journals]
▶ An Unlikely Biotech Investor: The Government   [Jun-08-18 09:14AM  Forbes]
▶ Achaogen: 1Q Earnings Snapshot   [May-04-18 07:56AM  Associated Press]
▶ Achaogen, Inc. to Host Earnings Call   [06:15AM  ACCESSWIRE]
▶ Achaogen Stock Trading Halted Today   [07:05AM  GlobeNewswire]
▶ Peninsula anti-aging drug company files for $85M IPO   [Apr-06-18 11:19AM  American City Business Journals]
▶ [$$] A Billionaire's Latest Biotech Bet   [Apr-04-18 01:00PM  Barrons.com]
▶ 7 Well-Known Stocks That Are Set to Reverse Direction   [Mar-26-18 02:18PM  TheStreet.com]
▶ 2 Small Biotechs That Continue to Look Good   [Mar-25-18 09:00AM  TheStreet.com]
▶ Achaogen Announces New Employment Inducement Grants   [Mar-22-18 08:01AM  GlobeNewswire]
▶ When Can We Expect A Profit From Achaogen Inc (NASDAQ:AKAO)?   [Mar-05-18 10:51AM  Simply Wall St.]
▶ Achaogen reports 4Q loss   [Feb-27-18 07:11PM  Associated Press]
▶ Achaogen, Inc. to Host Earnings Call   [12:20PM  ACCESSWIRE]
▶ Achaogen Announces New Employment Inducement Grants   [Feb-21-18 04:01PM  GlobeNewswire]
▶ Heres Whats Moving Bellicum Pharmaceuticals And Achaogen   [Jan-31-18 09:14AM  Market Exclusive]
▶ Here's Why Achaogen Inc Rose as Much as 16.9% Today   [Jan-30-18 01:45PM  Motley Fool]
▶ Achaogen Announces New Employment Inducement Grants   [Jan-25-18 08:00AM  GlobeNewswire]
▶ 3 Small-Cap Biotech Stocks With Major Catalysts in 2018   [Jan-06-18 10:24AM  Motley Fool]
▶ Achaogen to Present at J.P. Morgan Healthcare Conference   [Jan-03-18 04:01PM  GlobeNewswire]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.